<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609856</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr 111/2004</org_study_id>
    <secondary_id>0</secondary_id>
    <nct_id>NCT00609856</nct_id>
  </id_info>
  <brief_title>Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes</brief_title>
  <official_title>Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane County Council Research &amp; Development Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skane University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pioglitazone and insulin glargine are equally effective in achieving glycemic control in
      secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study was undertaken to assess differences in how insulin glargine vs.
      pioglitazone affect:

        -  Beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for
           insulin secretion (HOMA β-cell) and glucagon stimulated C-peptide test

        -  Insulin sensitivity as measured by adiponectin, homeostasis model assessment for insulin
           resistance (HOMA-IR) and insulin tolerance test and

        -  Surrogate markers of cardiovascular disease as measured by BNP, NT-pro BNP and plasma
           lipid profile as add-on therapy in patients with T2D and secondary drug failure. The
           patients' satisfaction with each treatment was also surveyed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of pioglitazone vs. insulin glargine on BNP</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Secondary Drug Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>tablet, 30 mg, once daily, 26 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>subcutaneous injection, start dose 6-10 units, once daily, 26 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes

          -  inadequately controlled on 50% of maximal-dose of an insulin secretagogue and
             metformin

        Exclusion Criteria:

          -  heart failure (NYHA II-IV)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif Groop, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Clinical Sciences, Division of Diabetes &amp; Endocrinology, Lund University, Malmö University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malmö University Hospital</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>January 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <last_update_submitted>January 24, 2008</last_update_submitted>
  <last_update_submitted_qc>January 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mozhgan Dorkhan/MD</name_title>
    <organization>Department of Clinical Sciences, Division of Diabetes &amp; Endocrinology</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

